AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
DexCom, Inc.
Video analysis: DXCM
All videosNo video analysis for this stock yet. Request one from our team.
News: DXCM
Dexcom Appoints Glenn Boehnlein to Board of Directors
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Glenn Boehnlein to its Board of Directors, effective September 10, 2026. Mr. Boehnlein is a highly accomplished healthcare executive and finance leader with more than 20 years of experience in the medical technology industry. Most recently, he served as Vice President and Chief Financial Officer of Stryker Corporation, one of the world's leading medical technology.
DexCom, Inc. (DXCM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
DexCom, Inc. (DXCM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services
Technical indicators have turned bullish for the three stocks.
Why DexCom (DXCM) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Dexcom Announces Upcoming Conference Presentation
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026. The live presentation is scheduled to begin at approximately 8:00 AM EDT and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for future reference. About DexCom, Inc. Dexcom em.
American Capital Management Inc. Purchases Shares of 235,152 DexCom, Inc. $DXCM
American Capital Management Inc. bought a new stake in DexCom, Inc. (NASDAQ: DXCM) in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 235,152 shares of the medical device company's stock, valued at approximately $15,837,000. American Capital Management Inc.
Abbott vs. DexCom: Which CGM Stock Is the Better Buy Now?
ABT edges DXCM on price-target upside and valuation, while both pursue CGM growth through innovation, adoption and strong liquidity.
Similar companies
-
STERIS plc
STE
·
New York Stock Exchange
Compare
-
Insulet Corp.
PODD
·
NASDAQ
Compare
-
Zimmer Biomet Holdings, Inc.
ZBH
·
New York Stock Exchange
Compare
-
Koninklijke Philips N.V.
PHG
·
New York Stock Exchange
Compare
-
Smith & Nephew plc
SNN
·
New York Stock Exchange
Compare
-
Labcorp Holdings Inc.
LH
·
New York Stock Exchange
Compare